RxDoctor Payments Data

Richard Parker, MD

Family Medicine · Cohocton, NYNPI 1710972013

Payments from drug & device makers

$810in general payments, 2019–2025

Across 46 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$281
  • AstraZeneca$127
  • Amarin Pharma, Inc.$96
  • Pfizer$60
  • Boehringer Ingelheim$47
  • GSK$40
  • plus $159 from 9 others

What the payments were for

  • Food & beverage$79598%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$810 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$750
Medicare patients
44
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$71,620
RybelsusSemaglutide36$67,005
EliquisApixaban64$65,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$32,856
JardianceEmpagliflozin29$31,606
FarxigaDapagliflozin Propanediol32$26,624
XareltoRivaroxaban15$13,540
Breo ElliptaFluticasone/Vilanterol27$12,751
Xtampza ErOxycodone Myristate23$10,803
Albuterol Sulfate HfaAlbuterol Sulfate201$6,827
JanumetSitagliptin Phos/Metformin Hcl13$6,565
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$5,840
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,293
Gabapentin284$4,376
Atorvastatin Calcium475$4,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$281$138,62596 claims
PfizerEliquis$60$65,41764 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$40$48,99080 claims
Boehringer IngelheimJardiance$47$31,60629 claims
AstraZenecaFarxiga, Symbicort$127$30,72044 claims
Johnson & JohnsonXarelto$14$13,54015 claims
AbbVieSynthroid$12$1,17425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Cohocton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →